A Pilot Study of Dose-Dense Paclitaxel with Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Neoplasm Recurrence, Local
  • Receptor, ErbB-2

abstract

  • The discontinuation rate during DD PTL was high, owing, in part, to an unexpectedly high incidence of rash. The trial was halted, because the initial discontinuation rate from overall toxicity made it unlikely that full accrual would demonstrate feasibility.

publication date

  • April 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4968930

Digital Object Identifier (DOI)

  • 10.1016/j.clbc.2015.09.009

PubMed ID

  • 26454612

Additional Document Info

start page

  • 87

end page

  • 94

volume

  • 16

number

  • 2